The discovery of hybridoma technology 25 years ago allowed researchers to isolate specifically defined monoclonal antibodies.1 Enthusiasm soared as researchers envisioned in their hands the magic bullet against cancer. Then reality hit: Many obstacles stood in the path toward using monoclonal antibodies as standard therapy. With Food and Drug Administration approval of Herceptin for certain breast cancer tumors last fall and Rituxan for B-cell lymphomas in 1997, cancer researchers have regained
 |
Monoclonal antibodies (MAbs) are analogous to guided missiles homing in on a target. When a foreign invader such as a virus or bacterium enters the body, the immune system produces an array of specific proteins called antibodies. Each plasma cell in the body is responsible for producing one type of antibody only, which acts specifically against a particular antigen, ...
A citizen science game explores how social choices and networks can influence how an illness moves through a population.
View this Issue
By fine-tuning polishing conditions, scientists attain high titers of infectious lentiviral particles during purification.
Learn how a next-generation platform accelerates biological research by enabling high-throughput, spatially resolved multiomics profiling.
In this webinar, Imogen Binnian will share how AI and gene synthesis technology can accelerate the discovery and validation of novel disease traits.
Real-time imaging enhances fluorescence activated cell sorting (FACS) to help scientists overcome the cost and burden of validation.
Industry-first smart HPLC system to provide authenticated user access verification on onboard touchscreen for superior security.
Setting new standards for intelligent mass detection, sensitivity, and sustainability.
Compact, Powerful, and now Mass Spec-Connected for Superior Analytical Performance
The Wellcome Sanger Institute, Helmholtz Munich, and Parse Biosciences have announced a landmark international collaboration to create a Cancer Plasticity Atlas.
